EIN 59-3097333

National Pediatric Cancer Foundation

IRS 501(c) type
Num. employees
Year formed
Most recent tax filings
NTEE code, primary
The National Pediatric Cancer Foundation, a nonprofit organization, dedicates itself to funding research aimed at eliminating childhood cancer. The NPCF's mission focuses on partnering with leading hospitals nationwide to fund research geared towards finding less toxic and more targeted therapies. It is run by David Frazer and located in Tampa, FL.
Total revenues
Total expenses
Total assets
Num. employees

Program areas at National Pediatric Cancer Foundation

The National Pediatric Cancer Foundation funds Pediatric Cancer research with the goal of leading to the treatment and elimination of Pediatric Cancer worldwide.we accomplish our mission through our research initiative, the sunshine project, an innovative collaboration of 30 hospitals nationwide. This collaborative research model is unique and effective in accelerating the development of new treatments against childhood cancer.see schedule o for further program service accomplishments.in developing this collaboration, the Foundation has brought together some of the country's leading investigators and institutions to drive the process of finding a cure. Investigators are performing three vital phases of research simultaneously: basic science, translational research and clinical trials. These major research components not only allow doctors to identify new agents in fighting Cancer, but also help researchers to understand the Cancer cells response to the drug. The National Pediatric Cancer Foundation is making great strides in its mission to find a cure for childhood cancer.current initiatives of the sunshine project are as follows:sarcoma trials (osteosarcoma, rhabdomyosarcoma, ewing sarcoma, non-rhabdomyosarcoma)1. Phase ii study of nab-paclitaxel in combination with gemcitabine for treatment of recurrent/refractory sarcoma in teenagers and young adultsthis trial will look at this combination of nab-paclitaxel and gemcitabine in its ability to prevent the formation or growth of tumors in teenagers and young adults with relapsed or refractory osteosarcoma, ewing sarcoma, rhabdomyosarcoma and other soft tissue sarcoma. The trial will also look at the length of time during and after treatment that the disease does not get worse,and determine if nab-paclitaxel combined with gemcitabine is safe and tolerable.2. A phase ib/ii study to evaluate the safety, feasibility and efficacy of nivolumab or nivolumab in combination with azacitidine in patients with recurrent, resectable osteosarcoma - this will be the first time both drugs, nivolumab and azacitidine are being used in combination to treat osteosarcoma3. Evolutionary inspired therapy for newly diagnosed, metastatic, fusion positive rhabdomyosarcomametastatic, fusion positive rhabdomyosarcoma (rms) have a poor outcome which is worsened with additional risk factors commonly called the oberlin criteria. Patients that meet all 4 oberlin criteria have an event free survival (efs) of less than 20% at 2 years. All therapeutic arms on this study are designed to meet the same primary aim of improving the 3 year event free survival from 6% to 35% for these patients. 4. Phase 1 trial of the lsd1 inhibitor sp-2577 in patients with relapsed or refractory ewing sarcoma)this trial is a targeted treatment for individuals diagnosed with refractory or recurrent ewing sarcoma, an aggressive, small round blue cell tumor typically presenting as a primary bone tumor in children and young adults.5. Tinks: a multi-institution study of tgf imprinted, ex vivo expanded universal donor nk cell infusions as adoptive immunotherapy in combination with gemcitabine and docetaxel in patients with relapsed or refractory Pediatric bone and soft tissue sarcomas (in development) - to determine the safety of the addition of adoptive transfer of universal donor, tgf imprinted (tgfi), expanded nk cells to gemcitabine/docetaxel (gem/dox) for treatment of relapsed and refractory sarcomas.brain tumor trial1. Action : adoptive cellular therapy following dose-intensified temozolomide in newly-diagnosed Pediatric high-grade gliomas - an immunotherapy trial for the treatment of high grade gliomas (hgg) in children2. Evaluation of digoxin for relapsed non-wnt, non-shh medulloblastoma (in development) this trial will evaluate the efficacy of digoxin in treating patients with relapsed non-shh, non-wnt medulloblastoma.non treatment trials1. Role of myeloid-derived suppressor cells (mdsc) in the development of immune tolerance after allogenic hematopoietic cell transplantation (allohct) -this is an observational trial with goal of better understanding the process of developing immune tolerance after blood and marrow transplantation (bmt). 2. Blood based biomarkers for minimal residual disease detection in Pediatric sarcomas - the purpose of this study is to see if detecting cell-free plasma tumor dna (ptdna) and circulating tumor cells (ctc) can predict recurrence of disease in patients who are in radiographic remission 2-3 weeks after treatment. Plasma tumor dna (ptdna) is free floating dna from the tumor found in the blood stream and circulating tumor cells3. Pediatric total Cancer care- this trial focuses on tissue and blood collection to further personalized medicine for children with cancertissue sample studies1. Comprehensive molecular profiling of rare Pediatric and aya cancers - development of an infrastructure, methods, and standard operating procedure to collect and procure histology specific (esthesioneuroblastom and embryonal sarcoma) tissue resources available throughout the sunshine project and associated repositories. Chart review study1. Comprehensive genetic profiling for Pediatric malignanciesongoing pre-clinical trials1. Assessment of expanded tumor infiltrating nk-cells collaborative2. Development of personalized rna loaded nanoparticles3. Fusion proteins by immunotherapysunshine project laboratorythe sunshine lab continues with the important task of finding promising new treatment regimens for sarcomas, among the most deadly Pediatric Cancer. During this past year, the sunshine lab has built on combination drug screening platform and focused on osteosarcoma and ewing sarcoma.pediatric sarcomas often shrink or go away with initial therapy but then later relapse and are then much more difficult to cure. This suggests that a small amount of disease eludes current therapy. We consider this small, resistant population should be the focus of preclinical research and have 3 major projects resulting from that understanding of Pediatric sarcoma. 1. We have developed a model of these two competing populations, termed heterogeneity, to figure out the best strategy to eliminate both Cancer cell populations with timing and combinations of therapies. 2. In collaboration, we are investigating "second strikes" in both osteosarcoma and ewing sarcoma. Second strikes are therapies after the disease has shrunk with initial therapy. Rather than shrink the tumor, we are investigating therapies to eliminate the residual cells better than continuing the initial therapy (first strike). This resulted from the sunshine lab participating in the 9th annual integrated mathematical oncology workshop at moffitt Cancer center. 3. In collaboration, we have focused on a new, non-mutated target in osteosarcoma, the cmg helicase. We have both identified this as a weakness in Cancer cells more than normal cells and identified a drug class that holds promise as an eventual therapy. We are exploring this agent alone and in combination to maximize the chance for a successful clinical trial. 4. In collaboration, we are building on prior publications show activity of epigenetic drugs like panobinostat and exploring mechanisms to enhance this therapy in osteosarcoma. 5. In collaboration, we are investigating an underappreciated dna repair enzyme as an achilles heel in ewing sarcoma called parp16.

Grants made by National Pediatric Cancer Foundation

GranteeGrant descriptionAmount
H Lee Moffitt Cancer Center and Research Institute FoundationIn Support of Clinical Trials Conducted Under the Sunshine Project.$850,000
Moffitt Cancer Center (MCC)In Support of Clinical Trials Conducted Under the Sunshine Project.$528,675
University of Alabama Donor Advised FundIn Support of Clinical Trials Conducted Under the Sunshine Project.$200,000
...and 14 more grants made

Who funds National Pediatric Cancer Foundation

Grants from foundations and other nonprofits
Leaving Legacies FoundationUnrestricted Contr To Public Charity$167,592
Schwab Charitable FundHealth$161,725
The 321 Project$100,000
...and 34 more grants received totalling $942,553

Personnel at National Pediatric Cancer Foundation

David FrazerChief Executive Officer$201,897
Austin BarnettCommunications Manager
Jim BassilSecretary$0
Alex SullivanChairman$0
Michael LevinTreasurer$0
...and 3 more key personnel

Financials for National Pediatric Cancer Foundation

RevenuesFYE 06/2022
Total grants, contributions, etc.$4,139,918
Program services$0
Investment income and dividends$99,773
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$0
Net income from fundraising events$109,437
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$0
Total revenues$4,349,128

Form 990s for National Pediatric Cancer Foundation

Fiscal year endingDate received by IRSFormPDF link
2022-062023-02-28990View PDF
2020-062021-02-19990View PDF
2019-062020-02-05990View PDF
2018-062018-12-22990View PDF
2017-062017-11-08990View PDF
...and 7 more Form 990s
Data update history
June 17, 2023
Posted financials
Added Form 990 for fiscal year 2022
May 8, 2023
Received grants
Identified 2 new grant, including a grant for $52,500 from Carley Family Foundation
August 2, 2022
Received grants
Identified 4 new grant, including a grant for $40,000 from Josephine S Leiser Foundation
July 9, 2022
Used new vendors
Identified 2 new vendors, including , and
September 24, 2021
Received grants
Identified 9 new grant, including a grant for $21,500 from Varnum-De Rose Trust
Nonprofit Types
Grantmaking organizationsDisease research fundraisersDisease-focused nonprofitsCharities
HealthDiseases and disordersMedical disciplinesCancer
Provides grantsConducts researchFundraising eventsNational levelReceives government fundingEndowed supportCommunity engagement / volunteeringTax deductible donations
General information
5550 West Executive Dr Suite 20
Tampa, FL 33609
Metro area
Tampa-St. Petersburg-Clearwater, FL
Hillsborough County, FL
Website URL
(813) 269-0955
Facebook page
Twitter profile
IRS details
Fiscal year end
Taxreturn type
Form 990
Year formed
Eligible to receive tax-deductible contributions (Pub 78)
NTEE code, primary
G30: Cancer
NAICS code, primary
813212: Health and Disease Research Fundraising Organizations
Parent/child status
Free account sign-up

Want updates when National Pediatric Cancer Foundation has new information, or want to find more organizations like National Pediatric Cancer Foundation?

Create free Cause IQ account